4CPS-034 Real-world study of trifluridine/tipiracil-bevacizumab in metastatic colorectal cancer

<h3>Background and Importance</h3> Due to the high incidence of this type of cancer in our area we consider it interesting to do this investigation. <h3>Aim and Objectives</h3> Evaluate the efficacy and safety of: tifluridine/tipiracil (TAS)-bevacizumab in patients with metastatic colorectal cancer (mCRC). <h3>Material and Methods</h3> Observational, retrospective study including patients with mCRCC treated with TAS-bevacizumab from 1 January 2022 to 30 July 2024. Variables collected: age, sex, ECOG and mutations, previous treatments, adverse events (AEs) and type of response using the electronic medical record DRAGO-AE. Efficacy has been evaluated in terms of progression-free survival (PFS) and overall survival (OS), defined as the time elapsed from the start of treatment to progression (PFS) or death (OS), calculated using the Kaplan-Meier method. Safety was assessed through the recorded treatment-related AEs, measuring their severity according to the Common Terminology Criteria for Adverse Events (CTCAEv4.0) toxicity scale. Descriptive statistical analysis was performed using SPSS-Statistics 22 software. <h3>Results</h3> 42 patients (29 men,13 women) whose median age was 62.5 (39–85) were included. The initial ECOG was 0–1 in 66.67% and 2 in 33.33%. KRAS mutation was present in 50% and BRAF in 4.77%. Treatment was prescribed as 2nd line in 2.38%, as 3rd line in 80.95% and as 4th line in 16.67%. The end of treatment was because of disease progression in 88.6%, toxicity in 5.7% and discontinuing in 5.7%. 83.33% of the patients presented AEs of any-grade and up to 53,38% of grade 3–4. The median PFS was 4.05 months (95% CI 3.38–4.71) and the median OS was 11.51 months (95% CI 7.57–15.45). The best response obtained during treatment was partial response in 2.38%, stable disease in 23.81%, disease progression in 54.76% and no response in 19.05% (50% exitus and 50% less than 3 cycles of treatment). <h3>Conclusion and Relevance</h3> The PFS obtained in our study was lower than that described in the SUNLIGHT study (5.6 months), this could be due to a greater number of patients starting treatment with an ECOG=2 in our study. The OS obtained in our study was longer compared to the literature (10.8 months). EAs of any-grade were similar to those described in the literature, but a lower percentage of grade 3–4 events were detected in our study. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest